CoTx-101 / Coave Therap - LARVOL DELTA

Coave Therapeutics to Present New Data on Wet AMD Gene Therapy Program at 26th Euretina Congress as it Advances towards the Clinic (GlobeNewswire) - "Dr. Nora Dimon, Coave’s VP of Clinical Development, will give an oral presentation evaluating the CoTx-101 program’s suprachoroidal delivery approach and dual-pathway therapeutic design, including non-human primate studies...In addition, Coave’s CEO, Rodolphe Clerval, will give an oral corporate presentation at the Euretina Innovation Spotlight (EIS) conference in Vienna, on 30 September 2026."

Preclinical • Wet Age-related Macular Degeneration